Expanded Access Program for arimoclomol
Associate Director, Patient Advocacy Relations
For more information visit orphazyme.com
Following last week’s news of positive data from the open label extension period of phase 2/3 trial in Niemann-Pick Disease Type C, Orphazyme is thrilled to announce availability of an Early Access Program (EAP) for those living with NPC in the U.S.
A communication from Orphazyme to the US NPC patient/parent community has also been shared which provides some direction for how interested families can obtain information about the program.